Advancements in the Management of Gynecological Cancers: ESMO 2024 - Episode 2
Key Findings from the PRIMA Trial: Niraparib in 1L Maintenance for Advanced Ovarian Cancer
Panelists discuss optimal durations for PARP inhibitor maintenance therapy in ovarian cancer, exploring how long patients are typically kept on PARPi in both first-line and second-line maintenance settings.
Video content above is prompted by the following:
- Briefly comment on key findings and final OS data from the PRIMA trial, evaluating niraparib 1L maintenance therapy in newly diagnosed advanced ovarian cancer.
- What implications do these findings have and what impact may they have on the treatment paradigm for ovarian cancer?
- What new insights can be drawn about long-term responders to maintenance niraparib from the recent subanalysis of the GEICO-88R study?
Related Content:
